10-Q: UTMD Q2 2025: Sales Decline, Profit Margins Contract

Utah Medical Products reports a decline in Q2 and H1 2025 revenues and net income, primarily due to reduced sales to a major OEM customer and lower gross profit margins.

Summary

• Net sales for Q2 2025 were $9,953K, a 4.3% decrease from Q2 2024, and $19,663K for H1 2025, a 9.6% decrease from H1 2024.
• Gross profit for Q2 2025 was $5,595K, down 10.5% from Q2 2024, and $11,133K for H1 2025, down 14.5% from H1 2024.
• Net income for Q2 2025 was $3,048K, an 11.7% decrease from Q2 2024, and $6,089K for H1 2025, a 17.8% decrease from H1 2024.
• Diluted earnings per share (EPS) for Q2 2025 was $0.939, a 4.0% decrease, and $1.858 for H1 2025, a 10.3% decrease.
• The decline in sales was largely driven by a continued decrease in sales to PendoTECH, accounting for 71% of the Q2 decline and 86% of the H1 decline.
• Domestic sales, excluding PendoTECH, increased by 7.6% in H1 2025.
• International sales (OUS) were lower than expected, decreasing by 15.5% in H1 2025 (11.6% lower excluding PendoTECH).
• Cash and investments stood at $82,179K as of June 30, 2025, a slight decrease from $82,976K at December 31, 2024.
• The company repurchased $6,708K of common stock (119,255 shares) in H1 2025 and paid $2,018K in cash dividends.
• Gross Profit margin contracted to 56.2% in Q2 2025 from 60.1% in Q2 2024, and to 56.6% in H1 2025 from 59.9% in H1 2024, primarily due to Ireland operations.
• Operating Income margin remained healthy at 32.1% in Q2 2025 and 32.3% in H1 2025.
• The company maintains a strong balance sheet with no debt, and a total debt ratio of 2.7% at June 30, 2025.

Sentiment

Score: 4

Explanation: While the company exhibits strong financial health with no debt, substantial cash reserves, and a commitment to returning capital to shareholders through dividends and buybacks, the recent performance shows a clear decline in sales, gross profit, and net income. The significant drop in sales to a key OEM customer (PendoTECH) and unexpected weakness in international markets are concerning. The potential for further revenue contraction due to tariffs and shipment delays adds uncertainty. However, the company's core domestic business (excluding PendoTECH) is growing, and management is actively pursuing strategic initiatives and maintaining profitability margins. The overall trend in key financial metrics is negative, but the underlying financial strength provides resilience.

Positives

• Maintains a strong balance sheet with no debt and a low total debt ratio of 2.7% at June 30, 2025.
• Continued share repurchases, totaling $6,708K in H1 2025, significantly mitigated the decline in Earnings Per Share.
• Consistently paid cash dividends to stockholders, totaling $2,018K in H1 2025.
• Domestic sales, excluding the impact of PendoTECH, increased by 7.6% in H1 2025.
• U.S. litigation costs were significantly lower, down $355K in Q2 2025 and $791K in H1 2025 compared to prior year periods.
• Maintained healthy Operating Income margins of 32.1% in Q2 2025 and 32.3% in H1 2025.
• Improved average inventory turns to 2.1 in Q2 2025 from 2.0 in Q4 2024.
• Strong current ratio of 41.9 at June 30, 2025, indicating robust liquidity.
• Average age of trade receivables improved to 33 days from 40 days at December 31, 2024.

Negatives

• Significant decline in net sales: 4.3% in Q2 2025 and 9.6% in H1 2025, primarily due to reduced sales to PendoTECH.
• Gross Profit margin contracted more than expected, falling to 56.2% in Q2 2025 and 56.6% in H1 2025.
• Net income decreased by 11.7% in Q2 2025 and 17.8% in H1 2025.
• Diluted EPS decreased by 4.0% in Q2 2025 and 10.3% in H1 2025.
• International sales (OUS) were lower than expected, with direct sales declining significantly in Ireland (27.4%), Canada (22.1%), Australia/New Zealand (20.6%), and France (21.4%) in H1 2025.
• Ireland operations' Gross Profit margin suffered due to an unfavorable product mix, lower sales absorbing less fixed manufacturing overhead, and higher raw material costs.
• Higher estimated average income tax provision rate (20.5% in Q2 2025 vs 18.0% in Q2 2024).
• Lower non-operating income due to lower interest rates in 2025 compared to 2024, resulting in approximately $332K less interest income in H1 2025.
• Inventory turns, despite improving, remain below management targets.

Risks

• Continued decline in sales to PendoTECH, with an expected $200K lower sales in 2H 2025 compared to 2H 2024, leading to a projected $2M total decline for 2025.
• Potential for reciprocal tariffs charged by foreign governments on goods sold OUS, which could substantially increase prices for OUS distributors and customers, thereby decreasing sales.
• A major China distributor has requested possibly delaying a final $800K shipment of blood pressure monitoring kits from Ireland from 2025 to 2026 due to possible tariffs, which would impact 2025 revenues and Ireland's Gross Profit margin.
• Difficulty in changing raw material suppliers due to regulatory standards requiring substantial validation for use in medical devices, potentially limiting ability to mitigate rising material costs.
• Ongoing Filshie clip product liability lawsuits, although the company does not expect the outcome to be material to consolidated financial results.
• General business risks and uncertainties as discussed in the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

Management expects 2H 2025 PendoTECH sales to be approximately $200K lower than 2H 2024, leading to total 2025 PendoTECH sales being about $2 million lower than 2024. Overall 2025 revenues are projected to be approximately 5% less than 2024 due to lower PendoTECH demand, potentially reaching 7% lower if a final $800K shipment to a major China distributor is delayed to 2026 due to possible tariffs. The beginning-of-year EBITDA target of $17-$18 million remains achievable. The Femcare IIA non-cash amortization expense is expected to be fully amortized in 1Q 2026.

Management Comments

• The lower sales in comparison with the prior years periods were dominated by a continued decline in sales to PendoTECH, representing 71% of the 2Q decline and 86% of the 1H decline.
• Although the negative PendoTECH sales comparisons are bottoming out, looking forward to the rest of the year, UTMD expects 2H of 2025 PendoTECH sales will be about $200 lower than in 2H 2024.
• UTMDs Gross Profit margin contracted more than expected in 2Q 2025 primarily as a result of lower sales than expected and an unfavorable product mix for UTMDs Ireland operations.
• UTMDs June 30, 2025 Balance Sheet continued strong, with no debt.
• Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans.
• If there are no better strategic uses for UTMDs cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.
• Targeting a high ROE of 20% remains a financial objective for UTMD management.
• Managements beginning of year EBITDA target of $17-$18 million continues to look achievable.

Industry Context

The medical device industry faces challenges from specific customer demand shifts, as evidenced by UTMD's significant sales decline to its major biopharmaceutical OEM customer, PendoTECH. International sales are also impacted by distributor ordering patterns and the increasing threat of reciprocal tariffs, which can raise costs for foreign customers and reduce demand. The sector also requires stringent regulatory validation for material changes, limiting flexibility in supplier selection. Despite these headwinds, the company operates in diverse medical specialties including obstetrics, gynecology, neonatal, and blood pressure monitoring, suggesting a diversified product portfolio within the broader medical technology landscape.

Legal Proceedings

• Ongoing Filshie clip product liability lawsuits are still in discovery.
• The company does not expect the outcome of the Filshie clip litigation to be material to consolidated financial results.

Stakeholder Impact

• Shareholders are impacted by lower EPS and Net Income, but benefit from continued cash dividends and share repurchases which mitigate EPS decline and demonstrate capital return.
• Customers, particularly the major OEM customer PendoTECH, have significantly reduced purchases, impacting overall sales.
• International customers and distributors face potential price increases due to reciprocal tariffs and have requested shipment delays, affecting sales volumes.
• Suppliers of raw materials are increasing prices, sometimes citing tariffs, which impacts the company's cost of goods sold, and changing suppliers is difficult due to regulatory validation requirements.

Next Steps

• Exploit pre-qualified status to market high-pressure process control transducer configurations directly to biopharmaceutical manufacturers.
• Continue leveraging OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations.
• Focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.
• Introduce additional products helpful to clinicians through product development.
• Utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued.
• Remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies.
• Evaluate the impact of adopting ASU 2023-09, effective for fiscal years beginning after December 15, 2024.
• Evaluate the impact of adopting ASU 2024-03, effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027.
• Femcare IIA non-cash amortization expense will be fully amortized in 1Q 2026.

Key Dates

Recommendation

While the company exhibits strong financial health with no debt, substantial cash reserves, and a commitment to returning capital to shareholders through dividends and buybacks, the recent performance shows a clear decline in sales, gross profit, and net income. The significant drop in sales to a key OEM customer (PendoTECH) and unexpected weakness in international markets are concerning. The potential for further revenue contraction due to tariffs and shipment delays adds uncertainty. However, the company's core domestic business (excluding PendoTECH) is growing, and management is actively pursuing strategic initiatives and maintaining profitability margins. Given the mix of strong underlying financial stability and capital allocation strategy against a backdrop of declining top-line and bottom-line performance, a 'hold' recommendation is appropriate. Investors should monitor the effectiveness of strategic initiatives, the stabilization of PendoTECH sales, and the impact of international trade dynamics.

Keywords

Medical devices, SEC filing, 10-Q, Financial results, Q2 2025, Utah Medical Products, UTMD, PendoTECH, Biopharmaceutical, Medical technology, Share repurchase, Dividends, Revenue, Net income, EPS, Gross profit margin, Operating income, Tariffs, International sales, Domestic sales, Filshie Clip System, Neonatal, Obstetrics, Gynecology, Electrosurgery, Urology, Blood pressure monitoring